This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
But other small biotechs are more advanced and still hope to play a role in the pandemic.
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
A move into the larger second-line breast cancer setting is surely on the way for the Astrazeneca and Daiichi drug.
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Despite industry outcry, new data question how relevant the rule would have been anyway.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
Pepaxto might not be a complete bust in myeloma.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The company has ambitious plans for its cell therapies, but money is tight.